These findings show that inhibition of CD200‐CD200R signalling significantly augments the cytotoxic potential of CIK cells towards AML blasts; CD200 can therefore be considered a good candidate for future CAR‐CIK‐based therapy in AML. The gene discussed is CD200R1; the disease is acute myeloid leukemia.